Monoclonal antibodies to type I interferon receptor

Abstract

Anti-IFNAR1 monoclonal antibodies with neutralizing activities against the anti-viral cytopathic effects of various type I interferons are provided.

1 . An anti-IFNAR1 monoclonal antibody that inhibits the anti-viral activity of a first type I interferon and does not inhibit the anti-viral activity of a second type I interferon selected from the group consisting of IFN-αA, IFN-αB, IFN-α II 1, and IFN-β.  
     
     
         2 . The monoclonal antibody of  claim 1  wherein the second type I interferon is IFN-β.  
     
     
         3 . The monoclonal antibody of  claim 2  wherein the first type I interferon is selected from the group consisting of IFN-αA, IFN-αB, and IFN-αG.  
     
     
         4 . The monoclonal antibody of  claim 3  that inhibits the anti-viral activity of IFN-αA, IFN-αB, and IFN-αG.  
     
     
         5 . The monoclonal antibody of  claim 4  that is designated 4A7, having ATCC Deposit No. HB 12132.  
     
     
         6 . The monoclonal antibody of  claim 4 , wherein the antibody recognizes a conformational epitope on IFNAR1.  
     
     
         7 . The monoclonal antibody of  claim 6 , wherein the antibody does not bind to a peptide consisting of the amino acid sequence of domain 1 (amino acids 1-200) of IFNAR1 and does not bind to a peptide consisting of the amino acid sequence of domain 2 (amino acids 204-404) of IFNAR1.  
     
     
         8 . The monoclonal antibody of  claim 4  that binds to one or more amino acids in situ in the sequence of amino acids 244-249 of IFNAR1, and binds to one or more amino acids in situ in the sequence of amino acids 291-298 of IFNAR1.  
     
     
         9 . The monoclonal antibody of  claim 8  that binds to amino acids 249, 291 and 296 of IFNAR1 in situ.  
     
     
         10 . The monoclonal antibody of  claim 9  that is designated 2E1, having ATCC Deposit No. HB 12133.